IBRX Stock Rises 8% As $100M Financing Boosts Balance Sheet

• The latest fund increases Oberland’s total committed capital to $375 million.
• Nant Capital converted $25 million of outstanding promissory notes into 4.6 million shares of common stock.
• ANKTIVA has received approval in 34 countries across five regulatory jurisdictions in under two years.

ImmunityBio, Inc. IBRX) announced on Tuesday that it has obtained $75 million in non-dilutive financing under its existing Royalty Interest Purchase Agreement (RIPA) with Oberland Capital, raising the total committed capital under the agreement to $375 million. 

The funding aims to strengthen the company’s balance sheet and boost its global expansion efforts. 

ImmunityBio stock traded over 8% higher on Tuesday morning. On Stocktwits, retail sentiment around the stock shifted to ‘bearish’ from ‘neutral’ territory the previous day amid ‘normal’ message volume levels. 

Strategic Debt-to-Equity Conversion

In parallel with the RIPA funding, Nant Capital, LLC, affiliated with ImmunityBio’s Executive Chairman Patrick Soon-Shiong, M.D., converted $25 million of the outstanding promissory note into 4.6 million shares of common stock.

This move has reduced the company's overall debt while reinforcing investor confidence. 

“The non-dilutive financing from Oberland and the conversion of debt to equity by Nant Capital, reflect strong confidence in ImmunityBio’s strategy and growth potential as a leading immunotherapy company paving the way for next-generation immunotherapy treatments.”

-Patrick Soon-Shiong, Founder and Executive Chairman, ImmunityBio

Global Regulatory Approvals Drive Expansion

ImmunityBio has rapidly expanded its global footprint with ANKTIVA, which has been approved in 34 countries across five regulatory jurisdictions in under two years.

ANKTIVA is a first-in-class IL-15 receptor designed to stimulate natural killer (NK) cells and CD8+ T cells, critical components of the immune response against tumors. By restoring memory T cell activity and overcoming tumor resistance, the therapy aims to produce durable clinical responses in patients with bladder and lung cancers.

IBRX stock has gained over 236% year-to-date. 

Also See: Trump Sends Stark Message To US Allies On Energy Crisis, Says ‘Go Get Your Own Oil’

For updates and corrections, email newsroom[at]stocktwits[dot]com.